Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-02-07

FDA Approved: BIKTARVY — Original Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a single-tablet regimen for the treatment of HIV-1 infection in adults and certain pe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

ORIG AP for BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)